Background: The complement system activation and regulation have been linked to post-transplant pathologies including chronic antibody mediated rejection (cAMR) and the recurrence of IgA nephropathy (ReIgAN) but distinct mechanisms remain to be elucidated. Methods: In this retrospective single center study, the outcome of kidney transplantation was studied in 150 patients with late histological diagnosis to be either cAMR or ReIgAN, 14 stable kidney grafts at 3 months and finally 11 patients with native kidney IgAN nephropathy. To study a role of complement cascade and regulation in cAMR and ReIgAN, the RNA was extracted from available frozen kidney biopsy samples and using RT-qPCR transcripts of 11 target genes along with clinical data were determined and compared with stable grafts at 3 months protocol biopsies or IgAN native kidney nephropathy. Immunohistologically, CD46 (MCP), and C5 proteins were stained in biopsies. Results: Interestingly, there were no differences in kidney graft survival between cAMR and ReIgAN since transplantation. cAMR was associated with significantly higher intragraft transcripts of C3, CD59, and C1-INH as compared to ReIgAN (p < 0.05). When compared to normal stable grafts, cAMR grafts exhibited higher C3, CD55, CD59, CFH, CFI, and C1-INH (p < 0.01). Moreover, ReIgAN was associated with the increase of CD46, CD55, CD59 (p < 0.01), and CFI (p < 0.05) transcripts compared with native kidney IgAN. Rapid progression of cAMR (failure at 2 years after biopsy) was observed in patients with lower intrarenal CD55 expression (AUC 0.77, 78.6% sensitivity, and 72.7 specificity). There was highly significant association of several complement intrarenal transcripts and the degree of CKD regardless the diagnosis; C3, CD55, CFH, CFI, and C1-INH expressions positively correlated with eGFR (for all p < 0.001). Neither the low mRNA transcripts nor the high mRNA transcripts biopsies were associated with distinct trend in MCP or C5 proteins staining. Conclusions: The intrarenal complement system transcripts are upregulated in progressively deteriorated kidney allografts.

Department of Clinical and Transplant Pathology Institute for Clinical and Experimental Medicine Prague Czechia

Department of Nephrology Transplant Center Institute for Clinical and Experimental Medicine Prague Czechia

Transplant Laboratory Transplant Center Institute for Clinical and Experimental Medicine Prague Czechia

Zobrazit více v PubMed

Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. . Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. (2009) 9:2520–31. 10.1111/j.1600-6143.2009.02799.x PubMed DOI

Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al. . Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation (2010) 90:68–74. 10.1097/TP.0b013e3181e065de PubMed DOI

Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant. (2014) 19:315–22. 10.1097/MOT.0000000000000072 PubMed DOI

Chand S, Atkinson D, Collins C, Briggs D, Ball S, Sharif A, et al. . The spectrum of renal allograft failure. PLoS ONE (2016) 11:e0162278. 10.1371/journal.pone.0162278 PubMed DOI PMC

Moroni G, Longhi S, Quaglini S, Gallelli B, Banfi G, Montagnino G, et al. . The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant. (2013) 28:1305–14. 10.1093/ndt/gfs472 PubMed DOI

Maixnerova D, Jancova E, Skibova J, Rysava R, Rychlik I, Viklicky O, et al. . Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994-2011. J Nephrol. (2015) 28:39–49. 10.1007/s40620-014-0090-z PubMed DOI

Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int. (1987) 31:820–9. 10.1038/ki.1987.72 PubMed DOI

Brodsky SV, Nadasdy GM, Pelletier R, Satoskar A, Birmingham DJ, Hadley GA, et al. Expression of the decay-accelerating factor (CD55) in renal transplants–a possible prediction marker of allograft survival. Transplantation (2009) 88:457–64. 10.1097/TP.0b013e3181b0517d PubMed DOI

Onda K, Ohsawa I, Ohi H, Tamano M, Mano S, Wakabayashi M, et al. . Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol. (2011) 12:64. 10.1186/1471-2369-12-64 PubMed DOI PMC

Park MS, Kim SK, Lee TW, Lee SH, Moon JY, Ihm CG, et al. . A promoter polymorphism in the CD46 complement regulatory protein gene is associated with acute renal allograft rejection. Transplant Proc. (2016) 48:809–12. 10.1016/j.transproceed.2015.12.126 PubMed DOI

Xie J, Kiryluk K, Li Y, Mladkova N, Zhu L, Hou P, et al. . Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol. (2016) 27:3187–94. 10.1681/ASN.2015111210 PubMed DOI PMC

Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. . Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. (2011) 11:2405–13. 10.1111/j.1600-6143.2011.03757.x PubMed DOI

Tran D, Boucher A, Collette S, Payette A, Royal V, Senécal L. Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature. Case Rep Transplant. (2016) 2016:9874261. 10.1155/2016/9874261 PubMed DOI PMC

Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, et al. . A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation (2015) 99:299–308. 10.1097/TP.0000000000000592 PubMed DOI

Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, et al. . Effect of the anti-C1s humanized antibody TNT009 and its parental mouse variant TNT003 on HLA antibody-induced complement activation-a preclinical in vitro study. Am J Transplant. (2017) 17:2300–11. 10.1111/ajt.14256 PubMed DOI PMC

Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. . Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. (2008) 8:753–60. 10.1111/j.1600-6143.2008.02159.x PubMed DOI

Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. . Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. (2010) 10:464–71. 10.1111/j.1600-6143.2009.02987.x PubMed DOI

Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. . Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant. (2012) 12:563–70. 10.1111/j.1600-6143.2011.03926.x PubMed DOI PMC

Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. . Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. (2014) 14:272–83. 10.1111/ajt.12590 PubMed DOI

Farrar CA, Sacks SH. Mechanisms of rejection: role of complement. Curr Opin Organ Transplant. (2014) 19:8–13. 10.1097/MOT.0000000000000037 PubMed DOI

Sheen JH, Heeger PS. Effects of complement activation on allograft injury. Curr Opin Organ Transplant. (2015) 20:468–75. 10.1097/MOT.0000000000000216 PubMed DOI PMC

Daha MR, van Kooten C. Role of complement in IgA nephropathy. J Nephrol. (2016) 29:1–4. 10.1007/s40620-015-0245-6 PubMed DOI PMC

Mosolits S, Magyarlaki T, Nagy J. Membrane attack complex and membrane cofactor protein are related to tubulointerstitial inflammation in various human glomerulopathies. Nephron (1997) 75:179–87. 10.1159/000189529 PubMed DOI

Fearn A, Sheerin NS. Complement activation in progressive renal disease. World J Nephrol. (2015) 4:31–40. 10.5527/wjn.v4.i1.31 PubMed DOI PMC

Cernoch M, Viklicky O. Complement in kidney transplantation. Front Med. (2017) 4:66. 10.3389/fmed.2017.00066 PubMed DOI PMC

Stevenson S, Mallett A, Oliver K, Hyland V, Hawley C, Malmanche T, et al. . Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant. Nephrology (2014) 19(Suppl. 1):22–6. 10.1111/nep.12195 PubMed DOI

Coppo R, Peruzzi L, Loiacono E, Bergallo M, Krutova A, Russo ML, et al. . Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. Nephrol Dial Transplant. (2018). [Epub ahead of print]. 10.1093/ndt/gfy064 PubMed DOI

Ehrengruber MU, Geiser T, Deranleau DA. Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett. (1994) 346:181–4. 10.1016/0014-5793(94)00463-3 PubMed DOI

Fischer WH, Jagels MA, Hugli TE. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol. (1999) 162:453–9. PubMed

Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Köhl J. The role of the anaphylatoxins in health and disease. Mol Immunol. (2009) 46:2753–66. 10.1016/j.molimm.2009.04.027 PubMed DOI PMC

Mahakur S, Saikia B, Minz M, Minz RW, Nada R, Anand S, et al. . Allo-specific immune response profiles indicative of acute rejection in kidney allografts using an in vitro lymphocyte culture-based model. Clin Exp Nephrol. (2018) 22:465–73. 10.1007/s10157-017-1469-7 PubMed DOI

Pan M, Zhang J, Li Z, Jin L, Zheng Y, Zhou Z, et al. . Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study. BMC Nephrol. (2017) 18:231. 10.1186/s12882-017-0658-7 PubMed DOI PMC

Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. . Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. (2013) 369:1215–26. 10.1056/NEJMoa1302506 PubMed DOI

Tillou X, Poirier N, Le Bas-Bernardet S, Hervouet J, Minault D, Renaudin K, et al. . Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int. (2010) 78:152–9. 10.1038/ki.2010.75 PubMed DOI

Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, et al. . C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study. Am J Transplant. (2016) 16:1596–603. 10.1111/ajt.13663 PubMed DOI

Farkas I, Baranyi L, Ishikawa Y, Okada N, Bohata C, Budai D, et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. J Physiol. (2002) 539(Pt 2):537–45. 10.1113/jphysiol.2001.013381 PubMed DOI PMC

Griesemer AD, Okumi M, Shimizu A, Moran S, Ishikawa Y, Iorio J, et al. . Upregulation of CD59: potential mechanism of accommodation in a large animal model. Transplantation (2009) 87:1308–17. 10.1097/TP.0b013e3181a19afc PubMed DOI PMC

A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence

Chronic Active Antibody-Mediated Rejection Is Associated With the Upregulation of Interstitial But Not Glomerular Transcripts